This protocol addresses the management of autosomal dominant tubulointerstitial kidney disease caused by a uromodulin (UMOD) gene mutation in patients who have developed gout.
ADTKD-UMOD arises from mutations in the uromodulin gene and is frequently associated with gout. Patients with UMOD-associated disease who develop gout will likely have further episodes, making early targeted intervention clinically important.
Management involves initiating urate-lowering therapy after the first gout attack has resolved. The specific agent selection, monitoring guidance, and safety considerations are detailed in the full structured protocol below.
Patients with UMOD-associated disease who develop gout will likely have further episodes.
Patients should therefore be started on allopurinol or febuxostat (when allopurinol cannot be tolerated) after the first attack of gout has resolved.
Allopurinol provides a good therapy for gout in this condition and may prevent further attacks.
DOI: 10.1038/ki.2015.28
View source ↗